-
Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery
•
German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial intelligence-driven precision drug design companies BenevolentAI (AMS: BAI) and Exscientia (NASDAQ: EXAI). These partnerships aim to discover potential first-in-class and best-in-class small-molecule therapies in the fields of oncology, neurology, and immunology. Terms of Collaboration and…
-
Novartis’s Aimovig Approved by China’s NMPA for Preventive Migraines Treatment
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its drug Aimovig (erenumab), a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb), which can now be used as a preventive treatment for adult migraines in China. Phase III…
-
Organon’s Liptruzet Approved in China for Hypercholesterolemia Treatment
•
US-based Organon (NYSE: OGN) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its drug Liptruzet (ezetimibe, atorvastatin), which is indicated for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) in China. DYSIS China Study and Liptruzet’s ImpactThe DYSIS China study reveals…
-
WuXi XDC Expands Manufacturing Capacity with New GMP Facilities in Wuxi
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement of GMP manufacturing at its state-of-the-art commercialization facilities, XBCM2 and XDP2, located in Wuxi. This development is anticipated to double the company’s…
-
CDE Releases 74th Batch of Generic Reference Preparations with 58 New Specifications
•
The Center for Drug Evaluation (CDE) has released the 74th batch of chemical generic reference preparations, marking a significant update to the list with the addition of 24 new specifications and an increment of 34 specifications in total. Review Outcomes and Specification DetailsEleven specifications did not meet the review criteria…
-
Roche’s Genentech Partners with Peptidream for First-in-Class PDCs in Radioisotope Therapy
•
Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has announced a partnership with Japan’s peptide-based therapeutics and diagnostics specialist, Peptidream (TYO: 4587). The collaboration aims to discover and develop potential first-in-class peptide-drug conjugates (PDCs) for the targeted delivery of radioisotopes against specific disease targets. Details of the PartnershipUnder the terms…
-
Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline
•
Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its Series C2 financing round. The round saw participation from the Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund, managed by China Grand Prosperity Investment, Haibang Venture, and Howbuy Primary Fund, with existing shareholders New…
-
Hainan Poly Pharm Submits DMF for Tecovirimat API to US FDA
•
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced the filing of a Drug Master File (DMF) with the US Food and Drug Administration (FDA) for its tecovirimat active pharmaceutical ingredients (APIs). This move signifies the company’s initiative to bring a potential treatment for poxvirus infections, including smallpox and…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
